Palo Alto Investors, LLC is an independent, privately owned investment advisor, registered with the Securities and Exchange Commission. The firm is located in Palto, California. Palo Alto Investors LLC submitted its SEC 13F filings for the period ended September 30, 2014, showing that United Therapeutics Corporation (NASDAQ:UTHR), Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), and Cubist Pharmaceuticals Inc (NASDAQ:CBST) are its top three holdings.
United Therapeutics Corporation (NASDAQ:UTHR) was top of the list of Palo Alto Investors, LLC, investments with investment worth $167.09 million. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company whose main focus is the development and commercialization of medical solutions for individuals suffering from chronic and life-threatening medical conditions. For the same quarter ended September 30, the largest shares of this company were held by Citadel Investment Group, which had 22.998 million shares, followed by QVT Financial with 22.5 million shares. (You can see complete list of hedge funds which hold positions on United Therapeutics Corporation (NASDAQ:UTHR) at the end of third quarter.)
The second largest investment of the firm was Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL), which accounted for a total of $144.91 million in investment value. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) is a fully integrated biotechnology company that produces and markets medical products for specialist uses, with the focus on some of the unmet areas. The company’s most recent third quarter results indicated that its total revenue for the period was $109.6 million, slightly higher than $108.1 million for the same quarter last year. The net income for the same period was $13.6 million.
Cubist Pharmaceuticals Inc (NASDAQ:CBST) emerged as the third largest investment of Palo Alto Investors, LLC, with investment valued at $122.31 million. Cubist Pharmaceuticals Inc (NASDAQ:CBST) is a biopharmaceutical company whose activities include the discovery, development, and marketing of pharmaceutical products. The company was recently upgraded to “buy” by TheStreet and given a ratings score of B-. The rating is driven by numerous positive factors that the analysts believe will have a lot of positive impact than the possible effects of any weaknesses. The latest report covering the stock, conducted by analysts at Credit Suisse, has however downgraded Cubist Pharmaceuticals Inc (NASDAQ:CBST) to “neutral” from “outperform.”
This article has been written by Victor Ochieng.
Related articles:
The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life
10 Vocational Skills in Demand Today with Jobs Waiting to be Filled